Investors have put together a $65 million series B to equip Iterum to take an antibiotic it picked up from Pfizer through a phase 3 trial in patients with uncomplicated urinary tract infections (uUTI).

In parallel to preparations for the uUTI trial, Iterum will work toward setting up a broader phase 3 program. Iterum sees sulopenem as an oral or intravenous treatment for gram-negative, multidrug resistant infections, notably the Enterobacteriaceae mutants of Escherichia coli and Klebsiella pneumoniae.